Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Mercado Continuo Espanol  >  Grifols SA       ES0171996012

Financials (€)
Sales 2016 4 154 M
EBIT 2016 1 044 M
Net income 2016 565 M
Debt 2016 3 461 M
Yield 2016 1,67%
Sales 2017 4 318 M
EBIT 2017 1 104 M
Net income 2017 650 M
Debt 2017 3 184 M
Yield 2017 1,85%
P/E ratio 2016 24,78
P/E ratio 2017 21,54
EV / Sales2016 3,91x
EV / Sales2017 3,70x
Capitalization 12 801 M
More Financials
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
07/28Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
07/11 GRIFOLS : FDA Approves Use of Zika Virus Assay to Screen US Blood Supply
07/05 PEDIGRI® : the tool that increases the information transparency to the plasma-de..
07/01 HOLOGIC : FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Gri..
06/29 GRIFOLS : Award Winner of the 2016 SPIN Awards Program
06/21 GRIFOLS : FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Gri..
06/16 GRIFOLS : confirms that it has voluntarily signed the EFPIA Code of Conduct
06/16 GRIFOLS : confirms that it has voluntarily signed the EFPIA Code of Conduct
06/14 JUNE 2016 TECH GUIDE : Immunoassay Analyzers
06/11 GRIFOLS : to Install the Kiro Oncology Robot at Smilow Cancer Hospital
06/02 GRIFOLS SA : ex-dividend day for annual dividend
More news
Sector news : Biopharmaceuticals
03:51p Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
01:45pDJEli Lilly Revenue Rise Helped by New Products
01:40pDJELI LILLY : Revenue Helped by Sales of New Drugs
09:25a Takeda sets bidding deadline for chemical firm stake, CVC and Carlyle may bid..
07/25DJSTADA ARZNEIMITTEL : Feels More Heat From Active Ownership
More sector news : Biopharmaceuticals
News from SeekingAlpha
01/04 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 21,8 €
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Víctor Grifols Roura Chairman, President & Chief Executive Officer
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Eva Bastida Tubau VP, Director-Scientific & Medical Affairs
Vicente Blanquer Torre Vice President-Quality, Research & Development
Ramón Riera Roca Executive Director, VP-Marketing & Sales
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA0.00%14 097
CSL LIMITED13.01%41 195
GRIFOLS SA-4.97%14 097
3SBIO INC-25.19%2 611
More Results